Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 31;22(1):173.
doi: 10.1186/s12985-025-02805-8.

"Silent messengers of chaos: unveiling the dual threat of immune infiltrates in Japanese encephalitis virus neuroinflammatory storm"

Affiliations
Review

"Silent messengers of chaos: unveiling the dual threat of immune infiltrates in Japanese encephalitis virus neuroinflammatory storm"

Naina Soni et al. Virol J. .

Abstract

The Japanese encephalitis virus (JEV), a neurotropic flavivirus, poses a formidable global health challenge due to its severe neurological sequelae and high lethality. Peripheral immune effectors, including monocytes, macrophages, dendritic cells, natural killer cells, and T lymphocytes, act as principal vectors of neuropathogenic exacerbation by translocating across a compromised blood-brain barrier (BBB). These cells perpetuate an inflammatory cascade within the central nervous system (CNS), characterized by unchecked cytokine dysregulation and collateral neuronal destruction. Exosomes, diminutive extracellular vesicles, emerge as cryptic propagators of JEV neuropathogenesis. Acting as molecular couriers, these vesicles disseminate viral RNA and proinflammatory mediators, thus orchestrating neuronal apoptosis and fostering a pernicious inflammatory microenvironment. Exosomal trafficking exacerbates BBB destabilization, potentiates immune cell ingress into the CNS, and establishes a deleterious feedback mechanism of neuroinflammation and cellular attrition. This review underscores the intricate crosstalk between peripheral immune infiltrates and exosomal vectors in JEV progression, advocating for advanced therapeutic paradigms aimed at intercepting exosomal biogenesis, attenuating immune hyperactivation, and preserving BBB integrity to mitigate CNS devastation.

Keywords: Japanese encephalitis virus; Blood-brain barrier dysregulation; Extracellular vesicles; Immune cell translocation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The schematic depicts the immune cell recruitment process during JEV pathogenesis, where infected monocytes serve as “Trojan horses,” accompanied by T cells. These cells traverse the disrupted BBB, fueled by JEV-triggered cytokine storms and endothelial damage, facilitating viral spread and neuroinflammation

Similar articles

References

    1. Zhang N et al. JEV Infection Induces M-MDSC Differentiation Into CD3 + Macrophages in the Brain, Front Immunol, vol. 13, no. April, pp. 1–17, 2022, 10.3389/fimmu.2022.838990 - PMC - PubMed
    1. Li N, et al. A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West nile virus in mice. NPJ Vaccines. 2020;5(1). 10.1038/s41541-020-00220-4. - PMC - PubMed
    1. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology introduction. 2 history of Japanese encephalitis virus. 2.1 discovery of the virus.and factors in transmission. 2.2 early studies on epidemic Japanese encephalitis in Japan 2.3 Epidemic Japanese Encephalitis.
    1. Redfield RR, et al. Japanese encephalitis vaccine: recommendations of the advisory committee on immunization practices morbidity and mortality weekly report recommendations and reports centers for disease control and prevention MMWR editorial and production staff. Serials) MMWR Editorial Board; 2019. - PMC - PubMed
    1. Mackenzie JS, Williams DT, van den Hurk AF, Smith DW, Currie BJ. Japanese Encephalitis Virus: The Emergence of Genotype IV in Australia and Its Potential Endemicity, Nov. 09, 2022, NLM (Medline). 10.3390/v14112480 - PMC - PubMed

LinkOut - more resources